This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.90% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Do Options Traders Know Something About Pacira BioSciences Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to PCRX stock based on the movements in the options market lately.
PCRXPositive Net Change
biotechnology biotechs medical
Apellis Stock Crashes 23% in a Week: Here's What You Should Know
by Zacks Equity Research
APLS stock plunges 23% in a week after reporting $190 million in preliminary Q4 U.S. net product revenues, as weaker Syfovre sales and mixed Empaveli uptake disappoint investors.
ALKSPositive Net Change FOLDNegative Net Change KRYSPositive Net Change APLSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why
by Zacks Equity Research
CGON expects phase III PIVOT-006 top-line data in first-half 2026, nearly a year early, after enrollment finished ahead of schedule across more than 90 sites.
MNKDPositive Net Change FOLDNegative Net Change KROSPositive Net Change CGONNegative Net Change
biotechs
How Will Mounjaro and Zepbound Sales Aid LLY's Upcoming Q4 Results?
by Ahan Chakraborty
Eli Lilly's Q4 revenues are expected to reflect strong Mounjaro and Zepbound demand, as supply gains and global uptake offset pricing pressure.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change GPCRNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Bayer Stock Jumps on Nubeqa Outlook, Presents Pharma Strategy
by Zacks Equity Research
BAYRY jumps 6.6% after partner Orion said Nubeqa sales tied to Bayer could top ???1B long term. Bayer also announced pharma priorities at J.P. Morgan Healthcare Conference.
JNJPositive Net Change BAYRYPositive Net Change CYTKPositive Net Change
biotechnology biotechs medical pharmaceuticals
KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026?
by Ekta Bagri
KROS shares are up 85.6% in a year, driven by a strategic review and pipeline progress led by KER-065 and elritercept, which have fueled investor enthusiasm.
SRPTPositive Net Change TAKNegative Net Change KROSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Moderna Stock on the Move: What Sparked the 13% Jump in the Past Week?
by Zacks Equity Research
MRNA shares rise after upbeat 2025 sales, stronger cash outlook and detailed 2026 guidance, alongside multiple pipeline milestones.
SNYPositive Net Change GSKPositive Net Change MRKNegative Net Change MRNAPositive Net Change
biotechs medical messenger-rna pharmaceuticals
Will DefenCath Continue to Aid CorMedix's Top Line in Q4 Earnings?
by Kanishka Das
CRMD's DefenCath, the only FDA-approved antimicrobial catheter lock, saw higher outpatient dialysis use in the fourth quarter, likely driving revenues.
PFEPositive Net Change AMPHNegative Net Change CRMDPositive Net Change
biotechs
ANIP Stock Rises 7% in a Week: Here's What You Should Know
by Sundeep Ganoria
ANI Pharmaceuticals jumps 7% as 2026 guidance tops expectations, with strong sales and EPS growth fueled by momentum in the rare disease franchise.
REGNPositive Net Change ABBVPositive Net Change ANIPNegative Net Change
biotechs medical
Will Positive Data on Camzyos Strengthen BMY's Cardiovascular Portfolio?
by Ekta Bagri
BMY reports positive late-stage data for Camzyos in adolescents with oHCM, expanding its cardiovascular outlook amid pipeline setbacks and rising competition.
BMYPositive Net Change JNJPositive Net Change CYTKPositive Net Change
biotechnology biotechs medical pharmaceuticals
TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA
by Zacks Equity Research
Travere Therapeutics shares fall after the FDA extends its review timeline for Filspari's sNDA in FSGS, pushing the decision date to April 2026.
KRYSPositive Net Change KROSPositive Net Change TVTXPositive Net Change IMCRNegative Net Change
biotechs
TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results
by Zacks Equity Research
TGTX jumps after preliminary 2025 sales beat guidance. Its bullish 2026 revenue target and multiple Briumvi pipeline milestones also draw attention.
MNKDPositive Net Change FOLDNegative Net Change TGTXPositive Net Change KROSPositive Net Change
biotechs
PCRX, LG Chem Partner to Expand Exparel Reach Across the Asia-Pacific
by Zacks Equity Research
Pacira BioSciences teams up with LG Chem to expand Exparel across Asia-Pacific, unlocking royalties and new revenue channels to support international growth.
ALKSPositive Net Change FOLDNegative Net Change PCRXPositive Net Change KRYSPositive Net Change
biotechnology biotechs medical pharmaceuticals
5 Stocks With Recent Price Strength to Maximize Your Gains
by Nalak Das
ISSC, AUGO, OWLT, KRYS and IDN are among a select group of stocks showing strong recent price momentum.
ISSCNegative Net Change IDNPositive Net Change KRYSPositive Net Change OWLTNegative Net Change AUGOPositive Net Change
aerospace basic-materials biotechs industrial-products tech-stocks
ADMA Biologics Reports Preliminary 2025 Results, Ups 2026 Outlook
by Zacks Equity Research
ADMA expects 2025 revenues of approximately $510-$511 million, raising 2026 guidance on strong Asceniv demand and margin expansion.
FOLDNegative Net Change ADMAPositive Net Change KRYSPositive Net Change
biotechnology biotechs medical pharmaceuticals
BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock Rises
by Zacks Equity Research
Beam Therapeutics jumps 22% after outlining 2026 pipeline goals, including accelerated approval plans for BEAM-302 and a potential risto-cel BLA filing.
BEAMPositive Net Change EXASNegative Net Change KROSPositive Net Change IMCRNegative Net Change
biotechs
ABBV Inks Drug Pricing Deal With Trump, Joins PD-1xVEGF Bandwagon
by Zacks Equity Research
AbbVie strikes a Trump drug-pricing pact and a $5.6B cancer licensing deal, cutting U.S. prices while expanding its oncology pipeline.
BMYPositive Net Change PFEPositive Net Change MRKNegative Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals
Novo Nordisk Soars 19% in a Month: How Should You Play the Stock?
by Ahan Chakraborty
NVO jumps nearly 19% in a month primarily on the FDA approval and launch of oral Wegovy, the first GLP-1 pill for obesity and cardiovascular risk reduction.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes
by Zacks Equity Research
SNY wins EU approval for Teizeild, the first disease-modifying drug to delay stage 3 type 1 diabetes in adults and children aged eight and older.
SNYPositive Net Change FOLDNegative Net Change MGNXPositive Net Change INDVPositive Net Change
biotechs
Will AbbVie's Oncology Segment Support Top-line Growth in Q4 Earnings?
by Sundeep Ganoria
ABBV's oncology unit is expected to post nearly 4% Q4 sales growth, as newer drugs offset weakness from declining Imbruvica demand.
AZNPositive Net Change PFEPositive Net Change MRKNegative Net Change ABBVPositive Net Change
biotechs earnings medical pharmaceuticals
KRYS Reports Preliminary Results for 2025, Outlines 2026 Objectives
by Zacks Equity Research
On a preliminary unaudited basis, Krystal Biotech expects revenues of $388-$389M in 2025. The company ended the year with $955M cash, and outlined 2026 plans as its pipeline advances.
FOLDNegative Net Change CRMDPositive Net Change KRYSPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
MDGL Secures Exclusive Global Right for MASH Treatment From PFE
by Zacks Equity Research
Madrigal Pharmaceuticals obtains global rights to Pfizer's ervogastat. It intends to pair it with Rezdiffra to advance combination therapies for MASH.
PFEPositive Net Change FOLDNegative Net Change CRMDPositive Net Change MDGLPositive Net Change
biotechs
PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates
by Zacks Equity Research
Pacira BioSciences stock slides nearly 10% after preliminary Q4 revenues of $196.9 million miss estimates, despite Exparel sales topping forecasts.
FOLDNegative Net Change PCRXPositive Net Change CRMDPositive Net Change INDVPositive Net Change
biotechnology biotechs medical pharmaceuticals
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug
by Zacks Equity Research
Teva strikes a $500M funding deal with Royalty Pharma for the speedy development of its vitiligo candidate, TEV-'408, while keeping global commercial control.
TEVAPositive Net Change RPRXPositive Net Change CRMDPositive Net Change INDVPositive Net Change
biotechnology biotechs medical pharmaceuticals
Exelixis Posts Preliminary '25 Results, Issues '26 Outlook
by Zacks Equity Research
EXEL posts approximately $2.32B in 2025 revenues and guides $2.525 -$2.625B for 2026 as Cabometyx grows and a zanzalintinib NDA advances.
RHHBYPositive Net Change EXELNegative Net Change FOLDNegative Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals